Suppr超能文献

不同种族胶质母细胞瘤患者中MGMT启动子甲基化的预后:一项荟萃分析。

The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis.

作者信息

Yang Haiyu, Wei Danping, Yang Kunxian, Tang Wenru, Luo Ying, Zhang Jihong

机构信息

Lab of Molecular Genetics of Aging and Tumor, Faculty of Medicine, Kunming University of Science and Technology, Kunming, 650500, Yunnan, China.

出版信息

Neurochem Res. 2014 Dec;39(12):2277-87. doi: 10.1007/s11064-014-1435-7. Epub 2014 Sep 18.

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene. Epigenetic silencing of the MGMT promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma (GBM) who receive alkylating agents. But the prognostic of MGMT promoter methylation in GBM patients of different race is still ambiguous. Based on an univariate or multivariate analysis between different race (Caucasian and Asian), a meta-analysis of the effects of MGMT promoter methylation on both progression-free survival (PFS) and overall survival (OS) among GBM patients was conducted. A total of 6,309 patients from 50 studies were involved in the analysis. Random effect models were applied to estimate the pooled hazard ratio (HR) with 95 % confidence intervals (CIs) for GBM patients of different race prognosis, the Chi square-based Q test was used to test heterogeneity. Begg's (funnel plot method) and Egger's linear regression tests were adopted to check publication bias (a bias with regard to what is likely to be published, among what is available to be published). The HR value estimated for OS was 0.524 (95 % CI 0.428-0.640) by univariate analysis and 0.427 (95 % CI 0.355-0.513) by multivariate analysis in Caucasian. The HR value estimated for OS was 0.892 (95 % CI 0.469-1.698) by univariate analysis and 0.562 (95 % CI 0.394-0.804) by multivariate analysis in Asian. The HR value estimated for PFS was 0.526 (95 % CI 0.372-0.743) by univariate analysis and 0.437 (95 % CI 0.356-0.537) by multivariate analysis in Caucasian. The HR value estimated for PFS was 0.132 (95 % CI 0.006-3.027) by multivariate analysis in Asian. This data revealed that GBM patients with MGMT promoter methylation had longer OS and PFS by univariate or multivariate analysis in Caucasian regardless of therapeutic intervention. However, GBM patients with MGMT promoter methylation only had longer OS by multivariate analysis in Asian.

摘要

O(6)-甲基鸟嘌呤-DNA甲基转移酶(MGMT)是一种DNA修复基因。MGMT启动子甲基化导致的表观遗传沉默会损害DNA修复,并与接受烷化剂治疗的胶质母细胞瘤(GBM)患者的更长生存期相关。但MGMT启动子甲基化在不同种族GBM患者中的预后仍不明确。基于不同种族(白种人和亚洲人)之间的单因素或多因素分析,对MGMT启动子甲基化对GBM患者无进展生存期(PFS)和总生存期(OS)的影响进行了荟萃分析。共有来自50项研究的6309名患者参与了分析。应用随机效应模型估计不同种族GBM患者预后的合并风险比(HR)及95%置信区间(CI),采用基于卡方的Q检验来检验异质性。采用Begg法(漏斗图法)和Egger线性回归检验来检查发表偏倚(关于可能发表的内容相对于可发表内容的一种偏倚)。在白种人中,单因素分析估计的OS的HR值为0.524(95%CI 0.428 - 0.640),多因素分析为0.427(95%CI 0.355 - 0.513)。在亚洲人中,单因素分析估计的OS的HR值为0.892(95%CI 0.469 - 1.698),多因素分析为0.562(95%CI 0.394 - 0.804)。在白种人中,单因素分析估计的PFS的HR值为0.526(95%CI 0.372 - 0.743),多因素分析为0.437(95%CI 0.356 - 0.537)。在亚洲人中,多因素分析估计的PFS的HR值为0.132(95%CI 0.006 - 3.027)。该数据显示,无论治疗干预如何,在白种人中,经单因素或多因素分析,MGMT启动子甲基化的GBM患者具有更长的OS和PFS。然而,在亚洲人中,经多因素分析,MGMT启动子甲基化的GBM患者仅具有更长的OS。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验